Glaukos (NYSE:GKOS) posted its second-quarter financial results this week and reported that it plans to acquire Avedro in an effort to build out its corneal health franchise. Avedro develops single-use drug formulations designed to strengthen corneal tissue and stop the progression of a degenerative corneal ectatic disease known as keratoconus. According to the Mass.-based company, the total U.S. […]
Glaukos licenses eye drug-delivery tech from Intratus
Glaukos (NYSE:GKOS) said today that it inked a licensing deal with Intratus for that company’s transdermal drug delivery platform for treating eye conditions. San Diego-based Intratus developed cream-based drug formulations that are applied to the outer eyelid to treat conditions such as dry eye disease, glaucoma, allergy, blepharitis and conjunctivitis. The deal gives San Clemente, Calif.-based […]
The 17 most innovative medical devices of 2019
The Galien Foundation recently announced nominees for most innovative medical devices for its 13th Annual Prix Galien USA Awards. The foundation awards the Prix Galien Award annually to examples of outstanding biomedical and technology product achievements that are designed to improve human condition. Nominees need to be FDA approved for market within the last five […]
Glaukos closes $3m Dose Medical buy
Glaukos (NYSE:GKOS) said yesterday that closed the nearly $3 million plus milestones to acquire former subsidiary Dose Medical and its drug-delivery technology for treating retinal diseases. Sam Clemente, Calif.-based Glaukos spun Dose out as a standalone company in 2010, but paid $26 million in July 2015 for Dose Medical’s glaucoma assets. Get the full story at our sister site, […]
Glaukos posts Street-topping Q1 earnings
Glaukos (NYSE:GKOS) yesterday posted first quarter 2019 earnings that topped both loss per share and sales expectations on Wall Street. The San Clemente, Calif.-based company posted losses of $1.3 million, or 4¢ per share, on sales of approximately $54 million for the three months ended March 31, seeing losses shrink 50.5% while sales grew 34.6% when […]
Glaukos, Santen ink U.S. MicroShunt distro deal
Glaukos (NYSE:GKOS) said last Friday that it inked a multi-year distribution deal with Santen Pharmaceutical (OTC:SNPHY) to market its MicroShunt device, intended to reduce intraocular pressure in patients with primary open-angle glaucoma (POAG), in the U.S. Through the deal, San Clemente, Calif.-based Glaukos will become the exclusive U.S. distributor of the MicroShunt, which is being studied in […]
Glaukos touts 5-year study of glaucoma stents
Glaukos (NYSE:GKOS) said today that a study of its iStent trabecular micro-bypass stents reduced eye pressure in glaucoma patients five years after implant. The same study showed that significantly fewer iStent patients needed add-on medications after five years, the company said. The study showed that newly diagnosed, primary open-angle glaucoma (POAG) patients who received two […]
Ivantis touts 2-year Hydrus, Glaukos iStent head-to-head study results
Ivantis today released two-year results from a study comparing its Hydrus Microstent to Glaukos‘ (NYSE:GKOS) iStent trabecular micro-bypass stents, touting reductions in medication use and no reoperations for patients in the Hydrus arm. The Irvine, Calif.-based company said that it is presenting results from the Compare trial today at the American Glaucoma Society’s annual meeting in […]
Glaukos rises on Street-beating Q4, 2018 earnings
Shares in Glaukos (NYSE:GKOS) are rising today after the ophthalmological-focused medical device maker posted fourth quarter and full year 2018 earnings that topped expectations on Wall Street. The San Clemente, Calif.-based company posted profits of approximately $1.8 million, or 4¢ per share, on sales of approximately $54.1 million for the three months ended December 31, for […]
Glaukos inks R&D deal for glaucoma therapy
Glaukos (NYSE:GKOS) has inked a research & development deal with Japanese biotech D. Western Therapeutics Institute to develop an intraocular glaucoma therapy. Glaukos and DWTI plan to evaluate products from the biotech’s compound library, as well as potentially synthesize new compounds as a part of the collaboration. Get the full story at our sister site, Drug Delivery […]
Glaukos shares fall on mixed-bag Q2
Shares in Glaukos (NYSE:GKOS) have fallen today after the ophthalmological device maker topped Wall Street sales consensus but missed on loss-per-share expectations with its second quarter earnings results. The San Clemente, Calif.-based company posted losses of $5.4 million, or 15¢ per share, on sales of $43.2 million for the three months ended June 30, seeing losses grow 63.5% […]
- 1
- 2
- 3
- …
- 5
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube